Ishara Investments LP Buys New Position in Oric Pharmaceuticals, Inc. $ORIC

Ishara Investments LP bought a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) during the 4th quarter, Holdings Channel.com reports. The firm bought 160,000 shares of the company’s stock, valued at approximately $1,309,000. Oric Pharmaceuticals comprises about 1.5% of Ishara Investments LP’s portfolio, making the stock its 23rd largest position.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Oric Pharmaceuticals by 48.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock valued at $55,802,000 after purchasing an additional 1,525,445 shares during the last quarter. State Street Corp raised its stake in Oric Pharmaceuticals by 77.1% during the fourth quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after buying an additional 1,854,458 shares during the last quarter. Orbimed Advisors LLC raised its stake in Oric Pharmaceuticals by 305.0% during the third quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock worth $43,701,000 after buying an additional 2,742,475 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Oric Pharmaceuticals by 14.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company’s stock worth $26,955,000 after buying an additional 423,795 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP bought a new position in Oric Pharmaceuticals during the fourth quarter worth $19,642,000. 95.05% of the stock is currently owned by institutional investors.

Oric Pharmaceuticals Price Performance

NASDAQ ORIC opened at $8.63 on Thursday. The business has a 50 day simple moving average of $9.00 and a 200 day simple moving average of $10.09. Oric Pharmaceuticals, Inc. has a one year low of $7.23 and a one year high of $14.93. The stock has a market capitalization of $893.38 million, a P/E ratio of -5.99 and a beta of 1.04.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, May 4th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Equities analysts expect that Oric Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ORIC shares. Oppenheimer reissued an “outperform” rating and set a $15.00 target price on shares of Oric Pharmaceuticals in a research note on Tuesday, February 24th. Citigroup decreased their target price on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Tuesday, April 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Friday, May 22nd. Finally, The Goldman Sachs Group raised Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Friday, May 15th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $18.92.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.